<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632264</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS9154</org_study_id>
    <nct_id>NCT04632264</nct_id>
  </id_info>
  <brief_title>Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping</brief_title>
  <acronym>PROCEEDING</acronym>
  <official_title>Optimal Timing of Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping - PROCEEDING (PostpaRtum OxytoCin Era dElayed corD clampING) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased blood loss after vaginal or cesarean delivery is one of the top causes of maternal&#xD;
      complications. Oxytocin is a common medication given to mothers by IV or an injection to&#xD;
      limit the amount of blood loss after delivery. The investigators do not know the best time&#xD;
      after delivery that oxytocin should be given. This research is being done to find out if&#xD;
      starting the medication oxytocin right after the baby is born or after the placenta comes out&#xD;
      decreases the amount of blood lost after birth when we delay cord clamping after birth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal timing of prophylactic oxytocin administration on both maternal and neonatal&#xD;
      outcomes has not been definitively established with delayed cord clamping. Maternal&#xD;
      considerations include the risk of postpartum hemorrhage, need for additional uterotonic&#xD;
      medications, need for maternal transfusion, retained placenta, and postpartum drop in&#xD;
      hemoglobin. Neonatal considerations include markers of neonatal well-being such as arterial&#xD;
      pH and 5-minute Apgar score, as well as hemoglobin and bilirubin levels. There is currently&#xD;
      no protocol on the timing of third stage prophylactic oxytocin and its administration is&#xD;
      based on physician/ delivery provider's preference. The investigators propose a quality&#xD;
      assessment initiative, through a randomized controlled trial designed to compare the blood&#xD;
      loss between administrations of prophylactic oxytocin immediately after delivery of the&#xD;
      neonate versus after delivery of the placenta with delayed cord clamping.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">April 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two parallel randomized, placebo-controlled, and double-blinded studies. For this study we will include 52 scheduled cesarean sections and 52 vaginal deliveries as two separate cohorts.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Randomization will be achieved using a computer generated algorithm. Both patient and provider will be unaware of the allocation arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Change defined as greater or equal to 1.0 g/dL (≥ 1 standard deviation (SD)) hemoglobin drop between the two arms following a vaginal delivery and greater or equal to 0.9 g/dL (≥ 1SD) following a cesarean delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Maternal Adverse Outcomes</measure>
    <time_frame>Postpartum, Up to 6 weeks</time_frame>
    <description>Any adverse maternal outcome (adverse event) including blood transfusion or symptomatic anemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Neonatal Adverse Outcomes</measure>
    <time_frame>Post Delivery, Up to 6 weeks</time_frame>
    <description>Any adverse neonatal outcome (adverse event) including jaundice, hematocrit laboratory abnormality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Pre-placental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin will be initiated immediately after delivery of the neonatal anterior shoulder (within 15 seconds). This is our &quot;intervention&quot; group. Saline placebo will be initiated post placenta delivery (within 15 seconds).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-placental group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds). Oxytocin will be initiated immediately after placenta delivery (within 15 seconds).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery</intervention_name>
    <description>The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride</description>
    <arm_group_label>Pre-placental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Initiation of standard postpartum oxytocin immediately following placenta delivery</intervention_name>
    <description>Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride</description>
    <arm_group_label>Post-placental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Saline placebo will be initiated post placenta delivery (within 15 seconds).</description>
    <arm_group_label>Pre-placental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).</description>
    <arm_group_label>Post-placental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All laboring women (induced, augmented, or spontaneous) at term admitted to Labor and&#xD;
             Delivery while comfortable&#xD;
&#xD;
          -  Scheduled cesareans&#xD;
&#xD;
          -  Women aged 18 years or older&#xD;
&#xD;
          -  Admitted at NewYork-Presbyterian Morgan Stanley Children's Hospital (CHONY) or Allen&#xD;
             Pavilion Labor and Delivery units&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multifetal gestation&#xD;
&#xD;
          -  Placental abruption or antepartum hemorrhage&#xD;
&#xD;
          -  Maternal bleeding disorder&#xD;
&#xD;
          -  Known fetal anomaly or anemia&#xD;
&#xD;
          -  Fetal growth restriction with abnormal Doppler&#xD;
&#xD;
          -  Significant maternal anemia (pre-operative hemoglobin ≤ 7g/dL&#xD;
&#xD;
          -  Intrapartum stillbirth&#xD;
&#xD;
          -  Placenta accreta spectrum&#xD;
&#xD;
          -  Abnormal placentation (previa or abruption)&#xD;
&#xD;
          -  Planned cord blood banking&#xD;
&#xD;
          -  Refusal of blood products&#xD;
&#xD;
          -  Any contraindication for delayed cord clamping&#xD;
&#xD;
          -  Maternal history of aortic stenosis or pulmonary hypertension or other severe cardiac&#xD;
             structural disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie E. Purish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McDonald SJ, Middleton P, Dowswell T, Morris PS. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst Rev. 2013 Jul 11;(7):CD004074. doi: 10.1002/14651858.CD004074.pub3. Review.</citation>
    <PMID>23843134</PMID>
  </reference>
  <reference>
    <citation>Soltani H, Hutchon DR, Poulose TA. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD006173. doi: 10.1002/14651858.CD006173.pub2. Review.</citation>
    <PMID>20687079</PMID>
  </reference>
  <reference>
    <citation>GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2. Erratum in: Lancet. 2017 Jan 7;389(10064):e1.</citation>
    <PMID>27733286</PMID>
  </reference>
  <reference>
    <citation>Rana N, Kc A, Målqvist M, Subedi K, Andersson O. Effect of Delayed Cord Clamping of Term Babies on Neurodevelopment at 12 Months: A Randomized Controlled Trial. Neonatology. 2019;115(1):36-42. doi: 10.1159/000491994. Epub 2018 Oct 2.</citation>
    <PMID>30278462</PMID>
  </reference>
  <reference>
    <citation>Andersson O, Lindquist B, Lindgren M, Stjernqvist K, Domellöf M, Hellström-Westas L. Effect of Delayed Cord Clamping on Neurodevelopment at 4 Years of Age: A Randomized Clinical Trial. JAMA Pediatr. 2015 Jul;169(7):631-8. doi: 10.1001/jamapediatrics.2015.0358.</citation>
    <PMID>26010418</PMID>
  </reference>
  <reference>
    <citation>Andersson O, Hellström-Westas L, Andersson D, Domellöf M. Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised controlled trial. BMJ. 2011 Nov 15;343:d7157. doi: 10.1136/bmj.d7157.</citation>
    <PMID>22089242</PMID>
  </reference>
  <reference>
    <citation>Committee Opinion No. 684: Delayed Umbilical Cord Clamping After Birth. Obstet Gynecol. 2017 Jan;129(1):1. doi: 10.1097/AOG.0000000000001860.</citation>
    <PMID>28002310</PMID>
  </reference>
  <reference>
    <citation>Purisch SE, Ananth CV, Arditi B, Mauney L, Ajemian B, Heiderich A, Leone T, Gyamfi-Bannerman C. Effect of Delayed vs Immediate Umbilical Cord Clamping on Maternal Blood Loss in Term Cesarean Delivery: A Randomized Clinical Trial. JAMA. 2019 Nov 19;322(19):1869-1876. doi: 10.1001/jama.2019.15995.</citation>
    <PMID>31742629</PMID>
  </reference>
  <reference>
    <citation>Hamm RF, Wang EY, Bastek JA, Srinivas SK. Assessing reVITALize: Should the Definition of Postpartum Hemorrhage Differ by Mode of Delivery? Am J Perinatol. 2017 Apr;34(5):503-507. doi: 10.1055/s-0036-1593535. Epub 2016 Oct 12.</citation>
    <PMID>27732984</PMID>
  </reference>
  <reference>
    <citation>Jackson KW Jr, Allbert JR, Schemmer GK, Elliot M, Humphrey A, Taylor J. A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol. 2001 Oct;185(4):873-7.</citation>
    <PMID>11641669</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

